Update on treatment of partial onset epilepsy: role of eslicarbazepine

References

• SemahFPicotMCAdamCIs the underlying cause of epilepsy a major prognostic factor for recurrence?Neurology1998515125612629818842
   PubMed Web of Science ®Google Scholar
• KwanPBrodieMJEarly identification of refractory epilepsyN Engl J Med2000342531431910660394
   PubMed Web of Science ®Google Scholar
• KwanPBrodieMJEpilepsy after the first drug fails: Substitution or add-on?Seizure20009746446811034869
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical ExcellenceClinical Guideline 20The epilepsies: The diagnosis and management of epilepsies in adults in children in primary and secondary care2004 Available from: http://www.nice.org.uk/CG020NICEguidelineAccessed 2010 Sep 21
   Google Scholar
• BrodieMJMumfordJPDouble-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study GroupEpilepsy Res19993423199205
   Web of Science ®Google Scholar
• KwanPBrodieMJRefractory epilepsy: Mechanisms and solutionsExpert Rev Neurother20066339740616533143
   PubMedGoogle Scholar
• KwanPBrodieMJCombination therapy in epilepsy: When and what to useDrugs200666141817182917040113
   PubMed Web of Science ®Google Scholar
• Johannessen LandmarkCJohannessenSIPharmacological management of epilepsy: Recent advances and future prospectsDrugs200868141925193918778117
   PubMed Web of Science ®Google Scholar
• Johannessen LandmarkCPatsalosPNDrug interactions involving the new second-and third-generation antiepileptic drugsExpert Rev Neurother201010111914020021326
   PubMed Web of Science ®Google Scholar
• JohannessenSIBen-MenachemEManagement of focal-onset seizures: An update on drug treatmentDrugs200666131701172516978035
   PubMed Web of Science ®Google Scholar
• BenesJParadaAFigueiredoAAAnticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f] azepine-5-carboxamide derivativesJ Med Chem199942142582258710411478
   PubMed Web of Science ®Google Scholar
• AlmeidaLFalcaoAMaiaJMazurDGellertMSoares-da-SilvaPSingle-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjectsJ Clin Pharmacol20054591062106616100301
   PubMed Web of Science ®Google Scholar
• AlmeidaLSoares-da-SilvaPSafety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humansDrugs R D20034526928412952496
   PubMedGoogle Scholar
• AlmeidaLSoares-da-SilvaPEslicarbazepine acetate (BIA 2-093)Neurotherapeutics200741889617199020
   PubMed Web of Science ®Google Scholar
• AmbrosioAFSoares-Da-SilvaPCarvalhoCMCarvalhoAPMechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024Neurochem Res20022712121130
   Web of Science ®Google Scholar
• Ben-MenachemEGabbaiAAHufnagelAMaiaJAlmeidaLSoaresda-SilvaPEslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsyEpilepsy Res2010892327828519939630
   PubMed Web of Science ®Google Scholar
• BialerMJohannessenSIKupferbergHJLevyRHPeruccaETomsonTProgress report on new antiepileptic drugs: A summary of the Seventh EILAT Conference (EILAT VII)Epilepsy Res2004611314815570674
   PubMed Web of Science ®Google Scholar
• BialerMJohannessenSILevyRHPeruccaETomsonTWhiteHSProgress report on new antiepileptic drugs: A summary of the Ninth EILAT Conference (EILAT IX)Epilepsy Res200983114319008076
   PubMed Web of Science ®Google Scholar
• Fontes-RibeiroCNunesTFalcaoAEslicarbazepine acetate (BIA 2-093) : Relative bioavailability and bioequivalence of 50 mg/mL oral suspension and 200 mg and 800 mg tablet formulationsDrugs R D20056525326016128595
   PubMedGoogle Scholar
• FrenchJAKannerAMBautistaJEfficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy SocietyEpilepsia200445541042315101822
   PubMed Web of Science ®Google Scholar
• McCormackPLRobinsonDMEslicarbazepine acetateCNS Drugs2009231717919062776
   PubMed Web of Science ®Google Scholar
• BialerMWhiteHSKey factors in the discovery and development of new antiepileptic drugsNat Rev Drug Discov201091688220043029
   PubMed Web of Science ®Google Scholar
• HainzlDParadaASoares-da-SilvaPMetabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(−)–10,11-dihydro-10-hydroxy carbamazepineEpilepsy Res20014423197206
   Web of Science ®Google Scholar
• ElgerCHalaszPMaiaJAlmeidaLSoares-da-SilvaPEfficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo-controlled, parallel-group Phase III studyEpilepsia200950345446319243424
   PubMed Web of Science ®Google Scholar
• Sierra-ParedesGNunez-RodriguezAVazquez-LopezAOreiro-GarciaTSierra-MarcunoGAnticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving ratsEpilepsy Res20067223140146
   Web of Science ®Google Scholar
• Sierra-ParedesGOreiro-GarciaMTVazquez-IllanesMDSierra-MarcunoGEffect of eslicarbazepine acetate (BIA 2-093) on latrunculin A-induced seizures and extracellular amino acid concentrations in the rat hippocampusEpilepsy Res2007771364317890056
   PubMed Web of Science ®Google Scholar
• Ben-MenachemEEslicarbazepine acetate: A well-kept secret?Epilepsy Curr20101017820126330
   PubMed Web of Science ®Google Scholar
• AlmeidaLNunesTSicardEPharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjectsActa Neurol Scand2010121425726420047572
   PubMed Web of Science ®Google Scholar
• AlmeidaLMinciuINunesTPharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsyJ Clin Pharmacol200848896697718508949
   PubMed Web of Science ®Google Scholar
• Gil-NagelALopes-LimaJAlmeidaLMaiaJSoares-da-SilvaPEfficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizuresActa Neurol Scand2009120528128719832771
   PubMed Web of Science ®Google Scholar
• ElgerCBialerMCramerJAMaiaJAlmeidaLSoares-da-SilvaPEslicarbazepine acetate: A double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizuresEpilepsia200748349750417319919
   PubMed Web of Science ®Google Scholar
• HalaszPCramerJAHodobaDLong-term efficacy and safety of eslicarbazepine acetate: Results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsyEpilepsia2010716 [Epub ahead of print]
   Web of Science ®Google Scholar
• MilovanDAlmeidaLRomachMKEffect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteersEpilepsy Behav201018436637320708576
   PubMed Web of Science ®Google Scholar
• AlmeidaLPotgieterJHMaiaJPotgieterMAMotaFSoares-da-SilvaPPharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairmentEur J Clin Pharmacol200864326727318157705
   PubMed Web of Science ®Google Scholar
• AlmeidaLSoares-da-SilvaPSafety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humansJ Clin Pharmacol200444890691815286095
   PubMed Web of Science ®Google Scholar
• LuszczkiJJThird-generation antiepileptic drugs: Mechanisms of action, pharmacokinetics and interactionsPharmacol Rep200961219721619443931
   PubMed Web of Science ®Google Scholar
• NunesTSicardEAlmeidaLPharmacokinetic interaction study between eslicarbazepine acetate and topiramate in healthy subjectsCurr Med Res Opin20102661355136220377319
   PubMed Web of Science ®Google Scholar
• GandhiMAweekaFGreenblattRMBlaschkeTFSex differences in pharmacokinetics and pharmacodynamicsAnnu Rev Pharmacol Toxicol20044449952314744256
   PubMed Web of Science ®Google Scholar
• FalcaoAMaiaJAlmeidaLMazurDGellertMSoares-da-SilvaPEffect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blockerBiopharm Drug Dispos200728524925617443646
   PubMed Web of Science ®Google Scholar
• Vaz-da-SilvaMAlmeidaLFalcaoAEffect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period studyClin Ther201032117919220171423
   PubMed Web of Science ®Google Scholar
• Fontes-RibeiroCMacedoTNunesTDosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: Randomized, open-label, crossover, single-centre study in healthy volunteersDrugs R D20089644745418989993
   PubMed Web of Science ®Google Scholar
• BarcsGWalkerEBElgerCEOxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsyEpilepsia200041121597160711114219
   PubMed Web of Science ®Google Scholar
• RemySBeckHMolecular and cellular mechanisms of pharmacoresistance in epilepsyBrain2006129Pt 1183516317026
   PubMed Web of Science ®Google Scholar
• RochaJFVaz-da-SilvaMAlmeidaLEffect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjectsInt J Clin Pharmacol Ther200947425526119356391
   PubMed Web of Science ®Google Scholar
• Vaz da SilvaMCostaRSoaresEEffect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjectsFundam Clin Pharmacol200923450951419500154
   PubMed Web of Science ®Google Scholar